Chapter 190：

"Well, the official news should come out soon." Li Zheng replied.

Guo Kezhen just walked to the neighborhood and turned his head when he heard the sound, his eyes contacted Li Zheng for a moment.

Li Zheng touched his nose and nodded to Guo Kezhen.

Guo Kezhen showed a complex look on his face, and after nodding to Li Zheng, he continued to attend the class. However, his next class became a lot more regular, and he no longer saw the enthusiasm when he just talked about gene editing technology.

The bell rang after class, the students pushed me and I pushed you, hesitatingly walked to the door of the classroom.

"Professor Guo, I'm sorry to come here without saying hello." Li Zheng showed an awkward look on his face. He thought that there were so many students in a classroom, and the chance of him sitting in a corner should be found out.

Guo Kezhen showed a polite smile on his face, "It is my honour for you to come and listen to my class, but it seems that I am a little bit tricky." He glanced over the dense notes in the notebook opened by Li Zheng. There was a hint of surprise.

"You laughed. In terms of genetics, I'm the one who makes the most of the trouble." Li Zheng paused, "I heard you didn't fight for the host of the Genome Project?"

He is not good at roundabouts, so he asked bluntly.

Hearing this, Guo Kezhen showed a trace of annoyance on his face. He did not sign up, which means that he showed weakness and gave up. There is no need for Li Zheng to remind him.

"Professor Li, this is my own business." Guo Kezhen said stiffly.

Li Zheng raised his eyebrows, said "Oh", and then said casually, "I have a lecture next Wednesday."

Obviously, if the preface is not followed by the words, it sounds like thunder in Guo Kezhen's ears.

Next Wednesday, next Wednesday is not the first meeting of the China Genome Project preparation team. The host of this China Genome Project will be selected at the meeting. What does Li Zheng mean for a lecture next Wednesday?

Did he not participate in the preparatory meeting?

This means... he gave up the opportunity to be the host of the Genome Project.

See Guo Kezhen looking at him with a look of madman.

Li Zheng chuckled lightly, showing a nice arc at the corner of his mouth.

"Professor Guo, people have self-knowledge. Well, I have some self-knowledge. In genetics, I can only be your student. I will continue to participate in promoting the Chinese Genome Project and international cooperation. We will cooperate in the future. Happy." With that, he stretched out his hand.

Guo Kezhen blankly opened his mouth, and after a long time he stretched out his hand and shook Li Zheng firmly.

After returning from Yan University, Li Zheng contacted Li Zheng's laboratory in Xiangjiang.

In the past three years, Li Zheng has ran between Hong Kong and Huajing. In addition to perfecting the technology of in vitro regeneration of organs, his other experience has been invested in the development of a human papillomavirus vaccine.

Many people may not know about human papillomavirus, but the HPV virus vaccine should be understood by future generations of female compatriots.

This is a vaccine that can prevent cervical cancer. Many people in later generations will call it the first vaccine that can prevent cancer. In fact, this statement is exaggerating. In Li Zheng's view, it was approved by the FDA in 1986. Hepatitis B vaccine is the first vaccine that can prevent cancer in a practical sense. Although it is clearly stated to prevent acute hepatitis when it is used in medicine, you have to admit that it does greatly reduce the incidence of liver cancer.

In the late 1980s and early 1990s, the German biologist Hausen had published the view that HPV is carcinogenic. However, even if the Hausen team discovered HPV16 and HPV18 and their carcinogenic mechanisms, pharmaceutical companies generally were skeptical. And after the publication of Howson's paper, a series of various reports came one after another, all refuting the carcinogenicity of HPV.

After erlotinib entered the FDA approval process, Li Zheng met the German biologist at an international anti-tumor conference. He is working to persuade international pharmaceutical companies to develop HPV vaccines.

Including GlaxoSmithKline and Merck, which produced HPV vaccines in later generations, both lacked interest in HPV vaccines at this time.

"Even now, biology can't fully explain the causal relationship between hepatitis B virus and liver cancer. He wants to repeat the miracle of hepatitis B virus, but he is too... anxious." Kent used an extremely tactful word.

Li Zheng raised his eyebrows, "But you have to admit that the hepatitis B vaccine has indeed made a great contribution to the history of humans against diseases."

Kent froze for a moment, then laughed, "Why, Li, are you interested in this HPV vaccine?"

Li Zheng smiled, "If I say I am interested."

Kent looked at Li Zheng for a long time, made sure that he had not lied again, and shrugged, "Then I might be able to submit an evaluation report to the review team."

Submitting an evaluation report to the review team is a very conservative statement. At the speed of the Merck review team, a project may not be completed in two or three years. Only some projects that are unpleasant and a pity to abandon are pharmaceutical companies. Will be submitted to the review team for review. This already shows Kent's attitude towards this project.

The carcinogenicity of HPV will gradually be recognized by the world biosphere after 1991, recognized by the biosphere, and valued by pharmaceutical companies, and then major research institutions will release the drug until the drug is available. It took 16 years in the previous life.

Li Zheng also made some achievements in vaccinology in his previous life. The studio under his name promoted the birth of domestic HPV vaccine. Before his sudden death, the HIV vaccine he presided over also showed good biological tolerance in biological trials, and its effectiveness reached more than 50%. In other words, given him another year or two, the HIV virus that the people of the world have heard of may be ended in his hands.

So Li Zheng approached Hausen and made a request for cooperation. For Hausen at this moment, someone willing to believe his views and invest a lot of money in vaccine development based on his views is already very pleased for him. .

What's more, Li Zheng did not put forward any overbearing requirements in the cooperation agreement. Hausen is completely able to continue to persuade other pharmaceutical companies to develop vaccines while developing drugs in Li Zheng's laboratory, which completely relieves Hausen from worrying about the future. .

So the old German man happily signed a cooperation agreement with Li Zheng.

Therefore, Li Zheng's laboratory began a three-year anti-cancer vaccine research.

So far, the HPV vaccine of Li Zheng’s laboratory has been able to protect against a variety of high-risk HPV types, including types 16 and 18. 70% of cervical cancers are caused by two subtypes of HPV16 and HPV18 viruses. In other words, the HPV vaccine developed by Li Zheng's laboratory can theoretically prevent 70% of cervical cancers.

It's just that vaccine clinical has always been a huge difficulty in drug development, and Li Zheng is also busy with this recently. He intends to use this as the first world-class drug clinical trial after the establishment of the domestic drug clinical trial specification. However, it is obvious that the domestic clinical risk assessment of this drug is too high. Li Zheng talked with the drug control department several times and got All are the answers that need to be studied.

"Li Zheng, Professor Howson hopes that the drug can enter the human clinical stage as soon as possible. What he means is that if China does not work, he can find a way in Germany." Zheng Lingling said.

In three years, enough for a newly graduated daughter to transform into a qualified career woman.

A drug patent can support a company. What's more, there are many high-value drug patents under the name of Li Zheng's laboratory. This is enough to make Zhenzhe Biology smooth in the pharmaceutical industry, and it has a good relationship with major international pharmaceutical companies. Relationship.

The only thing that is lacking is a work that allows the world to know the best, so Zheng Lingling is particularly concerned about this project.

Li Zheng rubbed his temples.

"Let me try again." Zhenzhe needs world recognition, as does China's pharmaceutical industry.

Zheng Lingling sighed, "Well, you are the boss, but Li Zheng, Zhenzhe is also your industry. The development of HPV has almost emptied all the patent funds you have accumulated. If you make a profit as soon as possible, you will pay back as soon as possible. I believe you Know this truth." The current President Zheng is not the little girl before, and she often makes Li Zheng speechless.

"Okay, okay, last time. I promise it will be the last time."

**

On April 10, 1990, the China Human Genome Project was officially launched in the Great Hall of the People. Guo Kezhen, the vice president of the Department of Biology of Yan University, the honorary president of the China Biogenetics Association, and the Chinese biologist Guo Kezhen was appointed The host of this plan.

There was thunderous applause in the hall.

"Is that kid Li Zheng really not here?" Zhao Depei applauded and set his eyes on the empty seat in the front row.

"He should be in Jinjiang University now." Old Tian said with a smile and turned his head.

"A liberal arts college, what kind of class will Li Zheng teach? How, they are determined to move toward a comprehensive college?"

"Who knows. But Xiao Zhao, how much do you know about the project Li Zheng has on hand?" Tian Xiangjun heard a little bit about the so-called small project Li Zheng had on hand, but he was also skeptical about it.

"I am not very clear about biology. If HPV virus and cervical cancer are really developed by him, the first anti-cancer vaccine in history, this title can still be worn."

“Hausen’s HPV carcinogenicity argument has mixed international reviews, and the clinical vaccine is still a cancer vaccine. This puts a lot of pressure on the clinic. No wonder they refuse to control the drug.”

"They don't want to. They want results but don't want to take risks. Pharaoh supports it, but there are too many people in the department who oppose it.

"The officials are not the same as the ones we do research. They are safe and creative. They will choose to pursue the latter while guaranteeing the former."